Akero Therapeutics (AKRO) Competitors $39.99 -1.96 (-4.67%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$40.00 +0.01 (+0.03%) As of 05:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO vs. RDY, MRNA, VTRS, ASND, QGEN, ROIV, LNTH, BBIO, RVMD, and LEGNShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Lantheus (LNTH), BridgeBio Pharma (BBIO), Revolution Medicines (RVMD), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Akero Therapeutics vs. Dr. Reddy's Laboratories Moderna Viatris Ascendis Pharma A/S Qiagen Roivant Sciences Lantheus BridgeBio Pharma Revolution Medicines Legend Biotech Dr. Reddy's Laboratories (NYSE:RDY) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking. Is RDY or AKRO more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to Akero Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.25% 17.87% 12.32% Akero Therapeutics N/A -32.46%-29.83% Does the media refer more to RDY or AKRO? In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 7 articles in the media. Dr. Reddy's Laboratories' average media sentiment score of 1.07 beat Akero Therapeutics' score of 1.03 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, RDY or AKRO? Dr. Reddy's Laboratories has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$311.31B0.04$668M$0.6321.01Akero TherapeuticsN/AN/A-$151.76M-$3.75-10.66 Do insiders & institutionals have more ownership in RDY or AKRO? 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 7.9% of Akero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, RDY or AKRO? Dr. Reddy's Laboratories has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Do analysts rate RDY or AKRO? Dr. Reddy's Laboratories presently has a consensus target price of $17.00, indicating a potential upside of 28.45%. Akero Therapeutics has a consensus target price of $76.29, indicating a potential upside of 90.76%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akero Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor RDY or AKRO? Dr. Reddy's Laboratories received 204 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 65.36% of users gave Akero Therapeutics an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% Akero TherapeuticsOutperform Votes11765.36% Underperform Votes6234.64% SummaryDr. Reddy's Laboratories beats Akero Therapeutics on 11 of the 16 factors compared between the two stocks. Remove Ads Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.18B$6.72B$5.53B$7.50BDividend YieldN/A2.80%4.86%4.05%P/E Ratio-10.666.9923.2318.08Price / SalesN/A198.60362.7586.83Price / CashN/A65.6738.1634.64Price / Book4.165.926.493.99Net Income-$151.76M$142.37M$3.21B$247.18M7 Day Performance-6.39%-7.24%-4.90%-4.25%1 Month Performance-10.20%-10.45%-0.07%-6.87%1 Year Performance74.10%-14.58%6.45%-3.73% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics4.1342 of 5 stars$39.99-4.7%$76.29+90.8%+72.5%$3.18BN/A-10.6630RDYDr. Reddy's Laboratories3.3037 of 5 stars$13.19-0.1%$17.00+28.9%-9.5%$11.01B$311.31B21.0024,800Positive NewsMRNAModerna4.2773 of 5 stars$28.35-8.9%$59.00+108.1%-74.6%$10.96B$3.20B-3.053,900High Trading VolumeVTRSViatris2.6159 of 5 stars$8.71+0.3%$10.50+20.6%-32.1%$10.40B$14.74B-11.7737,000ASNDAscendis Pharma A/S3.0183 of 5 stars$155.86+0.8%$204.64+31.3%+0.4%$9.46B$363.64M-21.951,017Positive NewsGap DownQGENQiagen3.4911 of 5 stars$40.17+0.8%$47.71+18.8%-0.9%$8.91B$1.98B111.866,030ROIVRoivant Sciences2.3564 of 5 stars$10.09-2.8%$17.10+69.5%-13.0%$7.20B$122.59M-67.26860LNTHLantheus4.3264 of 5 stars$97.60+1.5%$129.43+32.6%+64.2%$6.68B$1.53B16.24700Positive NewsGap DownBBIOBridgeBio Pharma4.5869 of 5 stars$34.57-1.5%$52.64+52.3%+16.6%$6.57B$221.90M-12.13400Insider TradeGap DownRVMDRevolution Medicines4.12 of 5 stars$35.36-5.3%$66.31+87.5%+4.7%$6.57B$742,000.00-9.85250Analyst ForecastPositive NewsGap DownLEGNLegend Biotech2.5889 of 5 stars$33.93-3.2%$79.00+132.8%-41.7%$6.23B$627.24M-35.721,070Short Interest ↓News CoveragePositive News Remove Ads Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Moderna Alternatives Viatris Alternatives Ascendis Pharma A/S Alternatives Qiagen Alternatives Roivant Sciences Alternatives Lantheus Alternatives BridgeBio Pharma Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKRO) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKRO Stock Free AKRO Stock Alerts